The significance of PI-RADS v2.1 score combined with quantitative parameters of DWI and DCE-MRI in differentiating between benign prostatic hyperplasia and prostate cancer

Abstract

This study investigates the efficacy of the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1) score combined with quantitative metrics from Diffusion Weighted Imaging (DWI) and Dynamic Contrast Enhancement Magnetic Resonance Imaging (DCE-MRI) in differentiating between benign prostatic hyperplasia (BPH) and prostate cancer (PCa). The data of 65 patients with prostate diseases were retrospectively analyzed, and they were divided into a BPH group (n = 34) and a PCa group (n = 31). All patients underwent a multiparametric MRI (mpMRI) examination, which included conventional MRI, DWI and DCE-MRI scans. Variables analyzed included the PI-RADS v2.1 score, apparent diffusion coefficient (ADC), volume transfer constant (Ktrans), rate constant (Kep) and extravascular space volume ratio (Ve). The diagnostic performance of the PI-RADS v2.1 score, DWI, DCE-MRI and their combined metrics in differentiating BPH from PCa was assessed using Receiver Operating Characteristic (ROC) curve analysis. The results demonstrated that the PI-RADS v2.1 scores, Ktrans and Kep values of the PCa group were significantly higher than those of the BPH group (p < 0.001), while the ADC value of the PCa group was significantly lower than the BPH group (p < 0.001). No significant difference was observed in the Ve value between the two groups (p = 0.596). ROC analysis indicated that the area under the curve (AUC) values for the PI-RADS v2.1 score, ADC, Ktrans, Kep , Ve and their combination parameters were 0.824, 0.916, 0.903, 0.904, 0.625 and 0.990, respectively, with the combined parameters showing higher sensitivity and specificity than any single parameter. These findings suggest that the PI-RADS v2.1 score, along with DWI and DCE-MRI sequences, are valuable tools for differentiating BPH from PCa. The quantitative parameters, including ADC, Ktrans and Kep values, offer significant imaging references for clinical assessment, and the combination parameters can significantly enhance diagnostic accuracy.

Keywords

• magnetic resonance imaging
• diffusion weighted imaging
• dynamic contrast enhancement
• benign prostatic hyperplasia
• prostate cancer